IVFhMG 75 Injection contains Menotrophin 75 IU, a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from the urine of postmenopausal women. It is indicated for use in assisted reproductive technologies, particularly in controlled ovarian hyperstimulation protocols to induce follicular development in women undergoing in vitro fertilization (IVF) or other fertility treatments. Menotrophin acts by stimulating the growth and maturation of ovarian follicles, thereby enhancing the chances of successful ovulation and fertilization. The dosage and duration of treatment should be individualized based on patient response, monitored through ultrasound and serum estradiol levels to minimize the risk of ovarian hyperstimulation syndrome (OHSS). IVFhMG 75 Injection is administered via intramuscular or subcutaneous injection, typically starting early in the menstrual cycle. Contraindications include primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, and hypersensitivity to menotrophins. Common adverse effects may include injection site reactions, abdominal discomfort, and ovarian enlargement. Careful monitoring by a fertility specialist is essential to optimize outcomes and reduce complications. IVFhMG 75 Injection is a critical agent in fertility management, facilitating ovulation induction in women with anovulatory infertility or those undergoing assisted reproduction.